It is called Vla2001 and is based on a technology already well established by many influenza vaccines and used in childhood. Antibodies 40% higher than AstraZeneca and better safety profile: but the latest data is still needed
The Committee for Human Medicines (CHMP) of the EMA (the European Medicines Agency) has launched an evaluation that starts the process of rapid approval for a new vaccine against Covid, Vla2001, developed by Valneva, a French biotechnology company.
Technology already proven on anti-flu
The decision is based on preliminary results from laboratory studies and early Phase 3 clinical trials in adults. This research suggests that the vaccine triggers the production of antibodies that target SARS-CoV-2 to an extent that exceeds the values of some of the vaccines in use and may help protect against disease. He comes injected in two doses 4 weeks apart. The novelty that VLA2001 is based on virus technology inactivated and the only one of its kind developed in Europe. The vaccine contains the same inactivated (killed) SARS-CoV-2 that can no longer cause the disease. Vla2001 also contains two adjuvants, substances that help strengthen the immune response to the vaccine. When a person is given the vaccine, their immune system identifies the inactivated virus as foreign and makes antibodies against it. a technology used for most flu vaccines and many vaccines administered in infancy with well-established levels of safety and efficacy and for this it could meet the demand of some people who do not look favorably on vaccines based on the new technology of the messenger RNA.
40% more antibodies than AstaZeneca
The Phase 3 study recruited a total of 4,012 participants aged 18 and over across 26 study sites in the UK. It was based on a control group that was not given a placebo, but the AstraZeneca vaccine (because with an increasing number of licensed vaccines, randomized placebo trials would not have been ethical). On October 18, Valneva announced the results: compared to Vaxzevria, VLA2001 produced 40% higher levels of antibodies that neutralized the coronavirus. He also produced fewer side effects. Participants aged 30 and older reported significantly fewer adverse events up to seven days after vaccination. The study was not published. Ongoing review of the data by EMA will continue until sufficient evidence is available for a formal marketing authorization application.
60 million doses optioned
The French firm announced on November 23 that it has signed an Advance Purchase Agreement (APA) with the European Commission to supply up to 60 million doses of its vaccine candidate in two years. The EU Commission stressed that the agreement also provides for the possibility that the vaccine is adapted to new variants of viral strains. It might as well be used for decoy, given that inactivated virus vaccines have been shown to be very effective in stimulating the immune response when administered after the full vaccination course.
December 3, 2021 (change December 3, 2021 | 12:05)
© REPRODUCTION RESERVED
#Ema #evaluates #Covid #vaccine #inactivated #virus #convince #vaxes